Signs Immunotherapy Is Working: What Doctors Look For

Waiting to learn whether cancer treatment is working can be one of the hardest parts of the treatment journey. A patient may notice less pain or more energy and wonder whether the cancer is shrinking. Another may feel tired after treatment and worry that nothing is improving.

Understanding the signs immunotherapy is working can make this uncertainty easier to manage. However, there is an important point to know from the beginning: symptoms alone cannot confirm a response.

Doctors usually look at several pieces of information together, including CT or MRI scans, tumor measurements, physical symptoms, laboratory results, and overall health. In some cancers, biomarkers may also add useful information. Moreover, immune checkpoint treatment can sometimes produce unusual response patterns that make an early scan harder to interpret.

This guide explains which changes are encouraging, which signs can be misleading, and how cancer specialists decide whether treatment should continue.

Signs Immunotherapy Is Working: What Doctors Actually Look For

The strongest evidence that treatment is helping usually comes from objective cancer assessments rather than from one symptom.

In clinical studies, patients receiving immune-based treatment are commonly evaluated with CT or MRI scans compared with images taken before treatment. Doctors may classify the cancer as showing a complete response, partial response, stable disease, or progression.

Encouraging findings can include:

• Tumors becoming smaller on imaging
• No new cancer sites appearing
• Existing tumors remaining stable
• Cancer-related symptoms becoming less severe
• Improved or stable ability to perform daily activities
• Certain tumor markers moving in a favorable direction when relevant
• Continued disease control across several follow-up scans

Importantly, stable disease can be a positive result in advanced cancer. A treatment does not always need to make every tumor disappear to provide meaningful benefit. Preventing cancer from growing or spreading may itself represent successful disease control.

1. Tumors Shrink on CT or MRI Scans

One of the clearest signs of treatment response is a measurable decrease in tumor size.

Doctors compare follow-up imaging with a baseline scan taken before treatment. CT scans are commonly used for tumors in the chest, abdomen, and pelvis, while MRI may be preferred for certain organs or brain lesions.

For example, imagine a patient begins treatment with several measurable lung lesions. At a later scan, those tumors are clearly smaller and no new lesions have developed.

That is much stronger evidence of response than simply saying the patient “feels better.”

Why One Scan Is Not Always the Whole Story

Immune-directed treatment can produce response patterns that differ from traditional chemotherapy.

In some cases, a tumor may initially appear larger before later shrinking. This phenomenon is known as pseudoprogression. Immune cells entering the tumor and inflammation around cancer tissue can contribute to an apparent increase in imaging even when treatment may ultimately be helping.

Because of these unusual patterns, researchers developed immune-specific response guidance known as iRECIST for clinical trials. It allows some apparent early progression to be confirmed on later imaging when the patient’s clinical condition makes continued treatment appropriate.

However, patients should not assume that every growing tumor represents pseudoprogression. True cancer progression remains possible and must be evaluated by the oncology team.

2. Cancer Remains Stable

People often expect successful cancer treatment to make tumors rapidly disappear. In reality, stopping cancer from growing can also be meaningful.

Stable disease means the cancer has not changed enough to be classified as either a clear response or clear progression.

For patients with advanced cancer, months or years of stable disease may represent valuable treatment benefits.

An NCI-listed study evaluating response after immune-based treatment, for example, includes patients with either partial response or stable disease when assessing whether they continue to derive clinical benefit.

This distinction matters because the goal of advanced cancer treatment is often long-term disease control rather than immediate elimination of every cancer cell.

3. Cancer-Related Symptoms Improve

Another encouraging clue can be improvement in symptoms caused directly by the tumor.

Depending on the cancer, a patient might notice:

• Less persistent pain
• Easier breathing
• Less coughing
• Better appetite
• Improved ability to walk or exercise
• Fewer symptoms caused by pressure from a tumor
• More ability to complete normal daily activities

These improvements can support the idea that treatment is helping, especially when scans show the same trend.

However, symptom improvement cannot confirm response by itself. Pain medicines, steroids, treatment of an infection, fluid drainage, radiation, or other supportive care may also improve how someone feels.

Likewise, a person may feel tired even while a tumor is shrinking because cancer treatment itself can cause fatigue. NCI notes that immune-based therapies can produce many side effects that vary according to the drug, cancer, dose, and patient’s overall health.

4. No New Tumors Appear

A good follow-up scan is not only about whether existing tumors became smaller.

Doctors also look carefully for new cancer sites.

If existing tumors remain stable and no new lesions appear, the treatment may be controlling the disease even when dramatic shrinkage has not occurred.

This is especially relevant in metastatic cancer, where stopping further spread can be an important treatment goal.

Conversely, new lesions may raise concern about disease progression. Because checkpoint therapy can occasionally produce unusual imaging patterns, however, the oncology team considers new findings alongside symptoms, timing, previous scans, and the overall clinical picture.

5. The Response Lasts Over Multiple Scans

A single encouraging scan is good news. Continued control over time is even more meaningful.

One of the reasons checkpoint inhibitors have changed cancer care is that some patients experience unusually durable responses.

In July 2026, the National Cancer Institute highlighted how checkpoint inhibitors have helped some patients with advanced melanoma, lung cancer, bladder cancer, and other cancers live longer and healthier lives. NCI also noted that checkpoint drugs such as pembrolizumab now have more than 40 treatment indications.

Durability is important because tumors can initially respond and later become resistant.

Therefore, oncologists continue performing follow-up assessments even after an excellent early response.

A pattern such as:

shrinkage → continued shrinkage → stable scans → no new disease

is generally more informative than one isolated scan.

6. Blood Tests May Support the Bigger Picture

Blood tests are often performed throughout cancer treatment, but routine blood results do not usually provide a universal yes-or-no answer about whether checkpoint therapy is working.

Some cancers produce measurable tumor markers, and changes may help doctors follow the disease. However, their value varies greatly by cancer type.

Researchers are also studying circulating tumor DNA, or ctDNA—small pieces of tumor-derived DNA found in blood.

NCI has described research exploring whether ctDNA could help measure treatment response, particularly when conventional imaging is complicated by effects such as pseudoprogression. However, liquid-biopsy approaches are not yet a universal replacement for scans in routine response assessment.

An active NCI-listed metastatic uveal melanoma trial, for example, incorporates ctDNA as a measurable biomarker for monitoring cancer status.

In short, blood-based response monitoring is promising, but its role depends heavily on the cancer and treatment setting.

7. Your Overall Performance Status Remains Strong

Doctors pay attention to more than tumors.

They also consider whether a patient is:

• Walking normally
• Eating adequately
• Maintaining daily activities
• Experiencing worsening cancer symptoms
• Losing strength rapidly
• Requiring increasing supportive care

A person whose cancer appears stable on scans and whose ability to function remains good may be considered to be receiving meaningful clinical benefit.

Some cancer trials specifically combine scan findings with performance status and clinical benefit when deciding whether treatment should continue.

This is why oncology appointments often include questions that may appear surprisingly ordinary: Are you eating? Are you walking? Has the pain changed? Are you sleeping more during the day?

Those details help create a fuller picture.

Do Side Effects Mean Treatment Is Working?

This is one of the most common misunderstandings.

Developing fatigue, rash, diarrhea, thyroid problems, or another immune-related reaction does not prove that the cancer is responding.

Research has explored whether immune-related side effects are associated with stronger treatment responses in some groups. However, the predictive value remains uncertain, and these reactions should not be used as a substitute for imaging and clinical assessment.

Similarly, having no side effects does not mean treatment has failed.

NCI emphasizes that side effects differ widely between patients and depend on factors including the treatment, dose, cancer type, disease stage, and baseline health.

Therefore:

Severe side effects ≠ proof of success.

No side effects ≠ proof of failure.

This is an important practical distinction because patients should never try to “push through” dangerous symptoms in the hope that stronger side effects mean stronger cancer control.

When Can You Expect Signs Immunotherapy Is Working?

There is no universal timeline.

Different cancers, drugs, combinations, and patients respond at different speeds. Some clinical studies perform response imaging around several weeks to a few months after treatment begins, but scan timing is determined by the specific treatment plan.

Moreover, delayed responses are possible with immune checkpoint drugs.

This is one reason the iRECIST framework recognizes that apparent early progression may sometimes require confirmation rather than an immediate assumption of treatment failure.

Patients should therefore ask their oncology team:

1. When is my first response scan?
2. What will you compare it with?
3. What would count as a good response?
4. Would stable disease be considered successful for me?
5. What would make you change treatment?

Those questions are often more useful than trying to judge treatment from symptoms between appointments.

Why Biomarkers Matter Before and During Treatment

Biomarkers can help doctors estimate whether some cancers are more likely to respond to immune checkpoint drugs.

Examples include:

• PD-L1
• Tumor mutational burden
• Mismatch repair deficiency
• Microsatellite instability
• Specific tumor and immune characteristics

NCI explains that biomarker testing can help determine whether checkpoint-based treatment may be appropriate, although no biomarker perfectly predicts response.

A 2025 NCI report also described an experimental artificial-intelligence model called SCORPIO that used routine blood tests and clinical data to predict response and survival after checkpoint treatment. In validation groups, its survival prediction performance ranged from about 72% to 76%, but additional research is needed before such tools become standard clinical practice.

The research direction is clear: doctors increasingly want to know not merely whether a drug works, but which patient is most likely to benefit from it.

Response Can Look Different Across Cancer Types

The basic principles of response assessment are similar, but the meaning of scan findings and biomarkers varies by cancer.

For immunotherapy for lung cancer, doctors commonly combine imaging with symptoms, tumor characteristics, and biomarkers such as PD-L1. Research continues to seek better tools for identifying patients most likely to respond because checkpoint drugs benefit only a portion of patients.

The side effects of immunotherapy for lung cancer also require careful interpretation because problems such as cough or shortness of breath could come from cancer, infection, or immune-related pneumonitis rather than treatment response. NCI identifies pneumonitis as an important inflammatory complication of checkpoint treatment.

Similarly, breast cancer immunotherapy is used in selected settings rather than across every breast cancer subtype, so response assessment must be interpreted within the specific treatment plan.

For immunotherapy for liver cancer, liver function and imaging are particularly important because changes in liver health may occur alongside changes in the tumor.

In other words, the same symptom may mean different things in different cancers.

How Does Immunotherapy Work Compared With Other Treatments?

If you have wondered how does immunotherapy work, the simplest explanation is that immune checkpoint drugs remove signals that normally limit T-cell activity.

Cancer can exploit these immune checkpoints and reduce the body’s ability to attack tumor cells. By blocking proteins such as PD-1, PD-L1, or CTLA-4, checkpoint medicines may restore a stronger antitumor response.

Other types of immunotherapy work differently, including cellular treatments that provide patients with specially selected or engineered immune cells.

That distinction matters when monitoring treatment.

The expected response pattern, side effects, and follow-up tests can differ depending on whether someone receives a checkpoint inhibitor, CAR T-cell treatment, TIL therapy, or another immune-based approach.

Can Immunotherapy Cure Stage 4 Cancer?

People understandably search can immunotherapy cure stage 4 cancer when scans begin showing a dramatic response.

Some patients with advanced cancers experience complete and long-lasting remissions after immune checkpoint treatment. NCI notes that these therapies have helped some people with advanced cancers live substantially longer. However, most patients do not achieve a permanent complete response, and some tumors eventually develop resistance.

Therefore, doctors often use terms such as:

• Complete response
• Partial response
• Stable disease
• Durable response
• Progression-free survival

rather than assuming that an excellent scan automatically means the cancer is cured.

Long-term follow-up remains necessary.

Signs That Treatment May Not Be Working

It is equally important to recognize findings that may concern the oncology team.

Possible evidence of true progression can include:

• Continued tumor growth across confirmed follow-up scans
• Multiple new metastatic sites
• Increasing cancer-related symptoms
• Declining physical function
• Growing tumor burden together with clinical deterioration

However, treatment should never be judged from symptoms alone.

For example, worsening fatigue could result from cancer progression, an immune-related thyroid problem, anemia, infection, another medication, or many other causes. NCI notes that checkpoint therapy can cause inflammation affecting the thyroid, pituitary gland, adrenal glands, lungs, digestive system, heart, and nervous system.

The cause needs to be investigated rather than guessed.

When New Symptoms Need Immediate Attention

A new symptom can occasionally signal treatment toxicity rather than cancer response.

Contact the cancer team promptly according to their instructions for symptoms such as:

• New or worsening shortness of breath
• Severe diarrhea
• Blood in stool
• Yellow skin or eyes
• Major muscle weakness
• Severe headache or confusion
• Chest pain
• Rapidly spreading rash
• Significant vision changes

Immune-related inflammation can affect several organs and occasionally become serious. Early recognition is important.

Do not wait for the next scan to mention a concerning symptom.

How Response Monitoring Is Changing in 2026

Cancer researchers are trying to move beyond relying only on standard scans.

On July 16, 2026, NCI described its Cancer Immune Monitoring and Analysis Centers and Cancer Immunologic Data Commons network as a program designed to perform detailed immune profiling of clinical-trial samples and identify biomarkers that could improve patient selection for immune treatment.

Days later, on July 21, 2026, NCI highlighted the enormous clinical impact of checkpoint inhibitors while emphasizing that resistance and patient selection remain major challenges.

Researchers are investigating:

• Blood-based biomarkers
• ctDNA
• Advanced imaging
• Immune-cell profiles
• Tumor genetics
• Artificial intelligence
• Better predictors of resistance

These approaches may eventually help doctors identify responses earlier and avoid ineffective treatment sooner.

For now, however, standard imaging and clinical assessment remain central.

A Note About Oral Immunotherapy

The phrase oral immunotherapy usually refers to allergy treatment, where controlled exposure to an allergen is used to reduce sensitivity. It should not be confused with standard immune checkpoint treatment used in oncology.

When researching immunotherapy for cancer, always check the exact medicine and treatment purpose rather than relying on the broad treatment name alone. NCI describes cancer immune treatment as a group of therapies that help the immune system fight cancer.

Signs Immunotherapy Is Working: Final Takeaway

The most reliable signs immunotherapy is working are not dramatic sensations after an infusion.

They are patterns.

Tumors shrink or remain stable. No new cancer appears. Cancer-related symptoms may improve. Daily function may remain strong. Most importantly, these findings continue across follow-up evaluations.

At the same time, checkpoint therapy can occasionally create unusual imaging patterns such as pseudoprogression, which is why one early scan may not always provide the final answer.

A practical way to approach treatment is to separate how you feel from what the cancer is doing. Both matter, but they answer different questions.

Report symptoms accurately. Attend scheduled scans. Ask what the images show compared with baseline. Find out whether stable disease would count as success in your particular situation.

Most importantly, do not assume that strong side effects mean treatment is effective—or that feeling completely normal means it is not.

The best assessment comes from the complete clinical picture interpreted by your oncology team.

Frequently Asked Questions

What is the first sign that immune treatment is working?

There is no single first sign. Tumor shrinkage or stable disease on follow-up imaging provides stronger evidence than symptoms alone. Doctors typically compare new CT or MRI results with baseline scans.

Does feeling better mean the cancer is shrinking?

It can be encouraging, especially if cancer-related pain or breathing problems improve. However, symptom changes alone cannot confirm tumor response; imaging and clinical assessment are still needed.

Does having no side effects mean treatment is not working?

No. Side effects vary widely between patients, and their absence does not establish treatment failure. NCI notes that reactions depend on the drug, dose, cancer, and individual health.

Can a tumor get bigger before getting smaller?

Yes, pseudoprogression can occur with immune checkpoint treatment. An initial scan may sometimes look worse before later improvement, which is one reason immune-specific response criteria were developed.

Is stable disease considered a successful response?

It can be. In advanced cancer, preventing tumors from growing or spreading may represent meaningful clinical benefit even when tumors do not shrink dramatically.